{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:22Z","timestamp":1788307222883,"version":"build-2803163510"},"reference-count":14,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1997,11,1]]},"abstract":"<jats:p>Background.\u2003The Advisory Committee on Immunization Practices recommends a second dose of measles, mumps, and rubella vaccine (MMR2) at age 4 to 5 years of age, whereas the American Academy of Pediatrics suggests MMR2 immunization at age 11 to 12 years of age. Because there is little information on whether the rate of adverse reactions to MMR2 immunization varies among these two age groups, we took advantage of differing immunization policies at two large HMOs to compare the frequency of clinical events after, and possibly related to, MMR2 immunization.<\/jats:p>\n               <jats:p>Methods.\u2003Information was collected on clinical events plausibly associated to MMR immunization (seizures, pyrexia, malaise\/fatigue, nervous\/musculoskeletal symptoms, rash, edema, induration\/ecchymoses, lymphadenopathy, thrombocytopenia, aseptic meningitis, and joint pain) in two cohorts. At three facilities at Northern California Kaiser (Oakland, CA), 8514 children received MMR2 immunization at age 4 to 6 years of age; at Group Health Cooperative (Seattle, WA) 18\u2009036 children received MMR2 immunization at age 10 to 12 years of age. To account for age-related differences in health care use, within each HMO, clinical events in a 30-day period after immunization were compared with a 30-day period before vaccination.<\/jats:p>\n               <jats:p>Results.\u2003Children 10 to 12 years of age were 50% more likely to have a clinical event after MMR2 immunization than in the period before immunization (odds ratio, 1.45; 95% confidence interval: 1.00,2.10). Children 4 to 6 years of age were less likely to have a visit for an event after immunization compared with the period before immunization (odds ratio, 0.64; 95% confidence interval: 0.40,1.01).<\/jats:p>\n               <jats:p>Conclusions.\u2003These results suggest that the risk for clinical events after MMR2 immunizations is greater in the 10- to 12-year age group.<\/jats:p>","DOI":"10.1542\/peds.100.5.767","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T23:40:17Z","timestamp":1092440417000},"page":"767-771","source":"Crossref","is-referenced-by-count":61,"title":["MMR2 Immunization at 4 to 5 Years and 10 to 12 Years of Age:  A Comparison of Adverse Clinical Events After Immunization in  the Vaccine Safety Datalink Project"],"prefix":"10.1542","volume":"100","author":[{"given":"Robert L.","family":"Davis","sequence":"first","affiliation":[{"name":"From the Group Health Cooperative, Seattle, Washington;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar Marcuse","family":"MD","sequence":"additional","affiliation":[{"name":"Children's Hospital Medical Center, Seattle, Washington;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Black","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Shinefield","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Givens","sequence":"additional","affiliation":[{"name":"From the Group Health Cooperative, Seattle, Washington;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Schwalbe","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Ray","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Thompson","sequence":"additional","affiliation":[{"name":"From the Group Health Cooperative, Seattle, Washington;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Chen","sequence":"additional","affiliation":[{"name":"National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Vaccine Safety Datalink Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[1997,11,1]]},"reference":[{"key":"2021121006423121700_B1","first-page":"1","article-title":"Recommendations of the Immunization Practices Advisory Committee (ACIP). Measles Prevention.","volume":"38","author":"Centers for Disease Control","year":"1989","journal-title":"MMWR"},{"key":"2021121006423121700_B2"},{"key":"2021121006423121700_B3"},{"key":"2021121006423121700_B4"},{"key":"2021121006423121700_B5","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/oxfordjournals.aje.a121318","article-title":"Clinical manifestations, according to age, among females given HPV-77 duck rubella vaccine.","volume":"94","author":"Swartz","year":"1971","journal-title":"Am J Epidemiol"},{"key":"2021121006423121700_B6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jama.1972.03210070037010","article-title":"Influence of age on clinical response to HPV-77 duck rubella vaccine.","volume":"202","author":"Weibel","year":"1972","journal-title":"JAMA"},{"key":"2021121006423121700_B7","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1542\/peds.99.6.765","article-title":"Vaccine Safety Datalink Project: a new tool for improving vaccine safety monitoring in the United States.","volume":"99","author":"Chen","year":"1997","journal-title":"Pediatrics"},{"key":"2021121006423121700_B8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/oxfordjournals.aje.a116479","article-title":"Confounding in studies of adverse reactions to vaccines.","volume":"136","author":"Fine","year":"1992","journal-title":"Am J Epidemiol"},{"key":"2021121006423121700_B9","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00000441-195409000-00013","article-title":"Modern measles.","volume":"228","author":"Babbott","year":"1954","journal-title":"Am J Med Sci"},{"key":"2021121006423121700_B10"},{"key":"2021121006423121700_B11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/oxfordjournals.aje.a112170","article-title":"Measles mortality: a retrospective look at the vaccine era.","volume":"102","author":"Barkin","year":"1975","journal-title":"Am J Epidemiol"},{"key":"2021121006423121700_B12","first-page":"307","article-title":"Measles mortality. Analysis of the primary cause of death.","volume":"129","author":"Barkin","year":"1975","journal-title":"JAMA"},{"key":"2021121006423121700_B13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00006454-199002000-00008","article-title":"Duration of live measles vaccine-induced immunity.","volume":"9","author":"Markowitz","year":"1990","journal-title":"Pediatr Infect Dis J."},{"key":"2021121006423121700_B14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00006454-199601000-00014","article-title":"Secondary failure rates of measles vaccines: a metaanalysis of published studies.","volume":"15","author":"Anders","year":"1996","journal-title":"Pediatr Infect Dis J."}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/100\/5\/767\/889997\/pe119700767o.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/100\/5\/767\/889997\/pe119700767o.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T15:27:17Z","timestamp":1639150037000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/100\/5\/767\/64590\/MMR2-Immunization-at-4-to-5-Years-and-10-to-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,11,1]]},"references-count":14,"journal-issue":{"issue":"5","published-online":{"date-parts":[[1997,11,1]]},"published-print":{"date-parts":[[1997,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.100.5.767","relation":{},"ISSN":["1098-4275","0031-4005"],"issn-type":[{"value":"1098-4275","type":"electronic"},{"value":"0031-4005","type":"print"}],"subject":[],"published":{"date-parts":[[1997,11,1]]}}}